|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Diagnostic Indicators for Blood Stasis Syndrome Patients with Gynaecological Diseases显示文摘Objective: To investigate the important diagnostic indicators for blood stasis syndrome(BSS) in patients of childbearing age with gynaecological diseases. Methods: A partial least squared-discriminant analysis(PLS-DA) were applied to BSS symptoms data of patients with gynaecological diseases, and the diagnostic indicators used by doctors of Korean medicine(DKMs) among BSS patients with gynaecological diseases were also investigated. Results: A total of 103 patients of childbearing age with gynaecological diseases and 40 healthy controls were enrolled. Among the 103 patients, 63(61.7%) and 40(38.8%) were diagnosed with BSS and non-BSS, respectively, and BSS patients exhibited a more severe extent of disease. A score plot of PLS-DA showed clearly different patterns among the 3 groups. Based on the variable importance on projection of PLS-DA model, menstrual pains, dark lumps in the menstrual blood, ileocoecal tenderness and resistance, sharp pains, and sublingual varicosities were selected as the top five most important indicators. Moreover, more than 75% of DKMs chose dark lumps in menstrual blood, menstrual pain, and dark menstrual blood as the diagnostic indicators of BSS in patients with gynaecological diseases, and more than 49% of them also considered sharp pains, dark red tongue, sublingual varicosities, and tendency to bruise easily as diagnostic indicators of BSS. Conclusion: DKMs focused on menstrual symptoms and certain gynaecological symptoms to diagnose BSS patients of childbearing age with female diseases. | Jeeyoun Jung Mi Mi Ko Myeong Soo Lee So Min Lee Ju Ah Lee | 2018 | Chinese Journal of Integrative Medicine2018，24，10： | 3 |
| 2 | A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma显示文摘 | Ko AH Youssoufian H Gurtler J | 2012 | Invest NewDrugs2012，30，4： | 1 |
| 3 | A phase II randomized studyof cetuximab and bevacizumab alone or in combination with gemc-itabine as first-line therapy for metastatic pancreatic adencarcinoma显示文摘 | Ko AH Youssoufian H Gurtler J | 2011 | Jun 1 [Epub ahead of print)2011，1，： | 1 |
| 4 | Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients显示文摘 | Ko JS Zea AH Rini BI | 2009 | Clin Cancer Res2009，15，6： | 1 |
| 5 | A phase II study of fixed -dose rate gemcitabine plus low- dose cisplatin fol- lowed by consolidative chemoradiation for locally advanced pancreatic cancer显示文摘 | KO AH QUIVEY JM VENOOK AP | 2007 | Int J Radiat Oncol Biol Phys2007，68，3： | 1 |
| 6 | S-nitrosylation of XIAP compromises neuronal survival in Parkinson′s disease显示文摘 | Tsang AH Lee YI Ko HS | 2009 | Proc Natl Acad Sci USA2009，106，12： | 1 |
| 7 | Optimizing the administra- tion of freed--dose rate gemcitabine plus capecitabine using an alter- nating-week schedule: a dose finding and early efficacy study in ad- vanced pancreatic and biliary carcinomas显示文摘 | Ko AH Espinoza AM Jones KA | 2012 | Am J Clin Oncol2012，35，5： | 1 |
| 8 | Temporal relationship between air pollutant and hospital admissionsfor chronic obstructive pulmonary disease in Hong Kong显示文摘 | Ko FW Tam W Wong TW Chan DP Tung AH Lai CK Hui DS | 2007 | Tho-rax2007，62，9： | 1 |
| 9 | Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer 显示文摘 | Ko AH Hwang J Venook AP | 2005 | Br J Cancer2005，93，2： | 1 |
| 10 | Pereutaneous radiofre- quency ablation: A novel treatment of facial venous malfor- marion显示文摘 | Kim AH Ko HK Won JY | 2009 | J Vasc Surg2009，50，2： | 1 |
| 11 | Phase Ⅱ study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcino ma of the pancreas显示文摘 | Ko AH Dito E Schillinger B | 2006 | J Clin Oncol2006，24，3： | 1 |
| 12 | Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy显示文摘 | Wong D Ko AH Hwang J | 2008 | Pancreas2008，37，3： | 1 |
| 13 | Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy 显示文摘 | Wong D Ko AH Hwang J | 2008 | Pancreas2008，37，3： | 1 |
| 14 | Schisandrin B decreases the sensitivity of mitochondriato calcium ion-induced permeability transition andprotects against carbon tetrachloride toxicity inmouse livers显示文摘 | Chiu PY Leung HY Siu AH Poon MK Ko KM | 2007 | Biol Pharm Bull2007，30，6： | 1 |
| 15 | Cavitary ulmonary lesions in patients infected with human immunodeficiency virus显示文摘 | Gallant JE Ko AH | | 0，，： | 1 |
| 16 | 推动消除疼痛治疗差异的国家议题:美国卫生政策、教育、医疗实践和研究指南(简版)显示文摘背景:疼痛会给个人和社会带来沉重负担。任何有关疼痛的法案都必须重点关注如何消除美国医疗体系内广泛存在的疼痛治疗差异问题。目标:本文主要关注与美国疼痛治疗差异性有关的,并有可能进行政策干预的宏观因素。方法:我们明确了可以实现疼痛治疗公平性的重要机会,特别是由近期美国医疗系统立法改革引出的机会。一个进取性的政策、倡议和研究议程由5个部分构成:①结构/系统;②政策和倡议;③医疗从业人员;④医疗服务提供者;以及⑤研究相关性。结果:疼痛治疗的不公平性是一个重要的卫生政策问题,但是却常常被忽视。平价医疗法案(ACA)中的许多直接和间接条款以及其他利用ACA法案推动的全国性计划都为实现疼痛治疗公平性提供了机会。这些机会包括对保险、社会、医疗服务提供者、立法者进行的教育改革,对初级医疗机构和疼痛专科医生培训方面进行改革、提高医疗从业人员的多样性、实现数据采集的种族/民族统一性、着重强调以患者为中心的转归研究,以及鼓励在疗效比较研究模式中关注疼痛治疗的差异性。结论:最近在ACA法案框架内发起的全国性立法倡议将会在多个层面上影响财政资金的流向,来解决医疗系统内广泛存在的治疗差异性问题。对疼痛治疗界来说,这是个绝佳的机会,可以首先利用这些全国性倡议,推进落实一项共同议题来解决疼痛治疗差异性的问题。 | Meghani SH Polomano RC Tait RC Vallerand AH Anderson KO Gallagher RM | 2014 | 中国疼痛医学杂志2014，20，2： | 1 |
| 17 | Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell car- cinoma patients 显示文摘 | Ko JS Zea AH Rini BI | 2009 | Clin Cancer Res2009，15，6： | 1 |
| 18 | Statin use and risk of pan?creatic cancer: results from a large, clinic-based case-control study显示文摘 | Walker EJ Ko AH Holly EA | 2015 | Cancer2015，121，8： | 1 |
| 19 | Absence of Autophagy-Related Proteins Expression Is Associated with Poor Prognosis in Patients with Colorectal Adenocarcinoma显示文摘 | Ji Hye Choi Young-Seok Cho Yoon Ho Ko Soon Uk Hong Jin Hee Park Myung Ah Lee Robert Odze | 2014 | Gastroenterology Research and Practice2014，，： | 1 |
| 20 | A PhaseI study of a 2-day Lapatinih chemosensitization pulse preceding nanoparticle albumin-bound paclitaxel for advanced solid malignancies显示文摘 | Chien AJ Illi JA Ko AH | 2009 | Clin Cancer Res2009，15，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员